Skip to main content
. Author manuscript; available in PMC: 2018 Oct 12.
Published in final edited form as: N Engl J Med. 2018 Apr 12;378(15):1396–1407. doi: 10.1056/NEJMoa1801445

Figure 4. (facing page). Relationship between DLBCL Genetic Subtypes and Survival after R-CHOP Chemotherapy.

Figure 4

Panels A and B show Kaplan–Meier models of progression-free survival and overall survival, respectively, according to DLBCL genetic subtype. Panels C and D show Kaplan–Meier models of progression-free survival and overall survival, respectively, among patients with ABC DLBCL according to genetic subtype and including patients with non-subtyped ABC cases as “other ABC.” Panel E shows a Kaplan–Meier model of overall survival among patients with GCB DLBCL cases belonging to the EZB subtype or not (“other GCB”). R-CHOP denotes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.